News Feature

Each year, Nature Biotechnology highlights companies that received sizeable early-stage funding in the previous year. Enlaza Therapeutics is developing protein-based therapeutics that bind irreversibly to their target.

Each year, Nature Biotechnology highlights companies that received sizeable early-stage funding in the previous year. City Therapeutics is using very small cityRNAs to broaden the range of siRNA therapeutics.

Each year, Nature Biotechnology highlights companies that received sizeable early-stage funding in the previous year. Seaport Therapeutics is modifying central nervous system drugs for delivery through the lymphatic system, bypassing first-pass liver metabolism.

Each year, Nature Biotechnology highlights companies that have received sizeable early-stage funding in the previous year. Vilya Therapeutics is designing macrocycle drug candidates.

Each year, Nature Biotechnology highlights companies that received sizeable early-stage funding in the previous year. Freya Biosciences is restoring balance in the vaginal microbiome to improve pregnancy outcomes.

For decades, and in the exceptional instance of the Institut Pasteur for over a century, non-profit organizations have augmented R&D to advance scientific understanding and develop affordable and accessible pipelines of vaccines, medicines and diagnostics. Small and medium enterprises and former biopharmaceutical industry executives make a sizeable contribution to global health goals by pursuing opportunities in this corner of the global biopharmaceutical ecosystem.

Chemical proteomics has brought rigor to covalent drug discovery and drugs to the clinic. Can it deliver a new generation of drug targets?

Today’s uniquely challenging biotech climate may result in a more resilient sector.

As the next generation of spatial transcriptomics tools hits the market, researchers are uncovering previously unknown interactions that could transform clinical research.

Developers are recombining or sharpening established drugs, molecules and mechanisms to create a new generation of neurology therapies.

After two volatile years, FDA approvals in 2024 settled closer to their 10-year average. Will nominated commissioner Marty Makary shake things up, or maintain a steady ship?

Merger and acquisition activity is at a seven-year low in 2024 as buyers digest prior deals and US election jitters delayed further spending. Expect a pick-up in 2025.

Each year, Nature Biotechnology highlights companies that have received sizeable early-stage funding in the previous year. Gate Bioscience wants to tailor gates that stop problematic proteins at the source.

Precision genetic methods are enabling more efficient, environmentally friendly pest control methods for agricultural use as well as stopping the spread of disease.

Each year, Nature Biotechnology highlights companies that have received sizeable early-stage funding in the previous year. Switch Therapeutics is rethinking cell-type specificity, building precision RNAi therapeutics for the brain.

Bacteria, fungi and plants can be grown and engineered to remove plastics, chemicals and pollutants from contaminated soil and water.

Each year, Nature Biotechnology highlights companies that have received sizeable early-stage funding in the previous year. Atomic AI generates the structure data it needs for its AI model with the aim of RNA drug discovery.

Each year, Nature Biotechnology highlights companies that have received sizeable early-stage funding in the previous year. A rescued chimeric antigen receptor from Cargo Therapeutics for hard-to-treat lymphomas shows promise in patients while a trispecific advances toward human testing.

After a difficult three years, biotech financing may slowly be returning to health.

Each year, Nature Biotechnology highlights companies that have received sizeable early-stage funding in the previous year. Indapta Therapeutics is using a subset of natural killer cells found in healthy donors to supercharge monoclonal antibodies to fight cancer and autoimmune disease.